Multicenter study on the monitoring of in vitro susceptibility to tigecycline in Santiago, Chile;Estudio multicéntrico de la vigilancia de la susceptibilidad in vitro a tigeciclina en Santiago de Chile

Revista Chilena de Infectologia

Volumn 26, Issue 3, 2009, Pages 220-226

  García C , Patricia ^a   Juliet L , Chrystal ^b   Fernández V , Alejandra ^b   San Martín S , Marcela ^c   Cifuentes D , Marcela ^d   Porte T , Lorena ^e   Braun J , Stephanie ^e   Castillo D , Loriana ^f   Vechiola H , Maggie ^g   Tapia P , Cecilia ^h   Sakurada Z , Andrea ⁱ   Chanqueo C , Leonardo ^h   Lam E , Marusella ^a   Espinoza P , Mónica ^a   Curcio F , Daniel ^j  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^b HOSPITAL DEL SALVADOR   (Chile)

^c HOSPITAL BARROS LUCO TRUDEAU   (Chile)

^d HOSPITAL SAN BORJA ARRIARÁN   (Chile)

^e HOSPITAL MILITAR DE SANTIAGO   (Chile)

^f Mutual de Seguridad Hospital   (Chile)

^g HOSPITAL SAN JOSÉ   (Chile)

^h HOSPITAL SAN JUAN DE DIOS   (Chile)

ⁱ HOSPITAL DR SÓTERO DEL RÍO   (Chile)

^j SRL   (Argentina)

more..

Author keywords

Agar diffusion method; Susceptibility; Tigecycline

Indexed keywords

ANTIINFECTIVE AGENT; DRUG DERIVATIVE; MINOCYCLINE; TIGECYCLINE;

ARTICLE; CHILE; CLINICAL TRIAL; DISK DIFFUSION; DRUG EFFECT; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; MULTICENTER STUDY;

ANTI-BACTERIAL AGENTS; CHILE; DISK DIFFUSION ANTIMICROBIAL TESTS; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HUMANS; MINOCYCLINE;

EID: 67749137139     PISSN: 07161018     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Petersen P J, Jacobus N V, Weiss W J, Sum P E, Testa R T. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936). Antimicrob Agents Chemother 1999; 43: 738-44.
2. Fluit A C, Florijn A, Verhoef J, Milatovic D. Presence of tetracycline resistance determinants and susceptibility to tigecycline and minocycline. Antimicrob Agents Chemother 2005; 49: 1636-8.
3. .Bauer G, Berens C, Projan S J, Hillen W. Comparison of tetracycline and tigecycline binding to ribosomes mapped by dimethylsulphate and drug-directed Fe2+cleavage of 16S rRNA. J Antimicrob Chemother 2004 53: 592-9
4. Pankey G A. Tigecycline. J Antimicrob Chemother 2005; 56: 470-80.
5. Zinner S H. Overview of antibiotic use and resistance: setting the stage for tigecycline. Clin Infect Dis 2005; 41: S289-92.
6. Noskin G A. Tigecycline: a new glycylcycline for treatment of serious infections. Clin Infect Dis 2005; 41: S303-14
7. Fritsche T R, Kirby J T, Jones R N. In vitro activity of tigecycline (GAR-936) tested against 11,859 recent clinical isolates associated with community-acquired respiratory tract and Gram-positive cutaneous infections. Diagn Microbiol Infect Dis 2004; 49: 201-9.
8. Sader H S, Jones R N, Dowzicky M J, Fritsche T R. Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit. Diagn Microbiol Infect Dis 2005; 52: 203-8.
9. .Sader H S, Jones R N, Stilwell M G, Dowzicky M J, Fritsche T R. Tigecycline activity tested against 26,474 bloodstream infection isolates: a collection from 6 continents. Diagn Microbiol Infect Dis 2005; 52: 181-6.
10. Hoban D J, Bouchillon S K, Johnson B M, Johnson J L, Dowzicky M J. Tigecycline Evaluation and Surveillance Trial (TEST Program) Group. In vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004). Diagn Microbiol Infect Dis 2005: 52; 215-27.
11. Gales A C, Jones R N, Andrade S S, Pereira A S, Sader H S. In vitro activity of tigecycline, a new glycylcycline, tested against 1,326 clinical bacterial strains isolated from Latin America. Braz J Infect Dis 2005: 9; 348-56.
12. Bouchillon S K, Hoban D J, Johnson B M, Stevens T M, Dowzicky M J, Wu D H, et al. In vitro evaluation of tigecycline and comparative agents in 3049 clinical isolates: 2001 to 2002. Diagn Microbiol Infect Dis 2005; 51: 291-5.
13. Bradford P A, Weaver-Sands T, Petersen P J. In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infections. Clin Infect Dis 2005; 41: S315-S332.
14. Wyeth Pharmaceuticals Inc. Tygacil Product Insert. Philadelphia, PA, USA, 2007. http://www.tygacil.com
15. Jones R N. Disk diffusion susceptibility test development for the new glycylcycline, GAR-936. Diagn Microbiol Infect Dis 1999; 35: 249-52.
16. Ruzin A, Keeney D, Bradford P A. AcrAB efflux pump plays a role in decreased susceptibility to tigecycline in Morganella morganii. Antimicrob Agents Chemother 2005; 49: 791-3.
17. Visalli M A, Murphy E, Projan S J, Bradford P A. AcrAB multidrug efflux pump is associated with reduced levels of susceptibility to tigecycline (GAR-936) in Proteus mirabilis. Antimicrob Agents Chemother 2003; 47: 665-9.
18. Morosini M I, García-Castillo M, Coque T M, Valverde A, Novais A, Loza E, et al. Antibiotic co-resistance in extended-spectrum-beta-lactamase-producing Enterobacteriaceae and in vitro activity of tigecycline. Antimicrob Agents Chemother 2006; 50: 2695-9.
19. Clinical and Laboratory Standards Institute. 2006. Performance standards for antimicrobial disk susceptibility tests; approved standard M2-A9, 9th ed. CLSI, Wayne, PA.
20. Stein G E, Craig W A. Tigecycline: a critical analysis. Clin Infect Dis 2006; 43: 518-24.
21. Dean C R, Visalli M A, Projan S J, Sum P E, Bradford P A. Efflux-mediated resistance to tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1. Antimicrob Agents Chemother 2003; 47: 972-8.
22. Henwood C J, Gatward T, Warner M, James D, Stockdale M W, Spence R P, et al. Antibiotic resistance among clinical isolates of Acinetobacter in the UK, and in vitro evaluation of tigecycline (GAR-936). J Antimicrob Chemother 2002; 49: 479-87.
23. Pachón-Ibáñez M E, Jiménez-Mejías M E, Pichardo C, Llanos A C, Pachón J. Activity of tigecycline (GAR-936) against Acinetobacter baumannii strains, including those resistant to imipenem. Antimicrob Agents Chemother 2004; 48: 4479-81.
24. Halstead D C, Abid J, Dowzicky M J. Antimicrobial susceptibility among Acinetobacter calcoaceticus-baumannii complex and Enterobacteriaceae collected as part of the Tigecycline Evaluation and Surveillance Trial. J Infect 2007; 55: 49-57
25. Peleg A Y, Adams J, Paterson D L. Tigecycline efflux as a mechanism for nonsusceptibility in Acinetobacter baumannii. Antimicrob Agents Chemother 2007; 51: 2065-9.
26. Navon-Venezia S, Leavitt A, Carmeli Y. High tigecycline resistance in multidrug-resistant Acinetobacter baumannii. J Antimicrob Chemother 2007; 59: 772-4.
27. Jones R N, Ferraro M J, Reller L B, Schreckenberger P C, Swenson J M, Sader H S. Multicenter studies of tigecycline disk diffusion susceptibility results for Acinetobacter spp. J Clin Microbiol 2007; 45: 227-30.
28. Curcio D, Fernández F, Jones R N, Ferraro M J, Reller L B, Schreckenberger P C, et al. Tigecycline disk diffusion breakpoints of Acinetobacter spp: a clinical point of view. J Clin Microbiol 2007; 45: 2095-6.
29. Petersen P J, Bradford P A. Effect of medium age and supplementation with the biocatalytic oxygen-reducing reagent oxyrase on in vitro activities of tigecycline against recent clinical isolates. Antimicrob Agents Chemother 2005 49(9): 3910-8